Emerging functions of p21-activated kinases in human cancer cells

Rakesh Kumar1, Ratna K Vadlamudi

  • 1Department of Molecular and Cellular Oncology, The University of Texas M.D. Anderson Cancer Center, Houston, Texas 77030, USA. rkumar@mdanderson.org

Insights

P21 activated kinases (Paks) are crucial for cell functions and are implicated in cancer. This review explores Pak functions and their role in tumorigenesis, highlighting novel interacting proteins.

Area of Science:

  • Molecular Biology
  • Cell Biology
  • Biochemistry

Background:

  • Paks are serine/threonine kinases regulating cell morphogenesis, motility, survival, mitosis, and angiogenesis.
  • Pak activation occurs via GTPase-dependent and -independent pathways, influenced by growth factors and extracellular signals.
  • Dysregulated Paks are linked to human tumors and neurodegenerative diseases.

Purpose of the Study:

  • To review current knowledge on the Paks family.
  • To explore emerging cellular functions of Paks.
  • To elucidate the contribution of Paks to cancer development.

Main Methods:

  • Literature review of studies on Paks.
  • Analysis of Pak involvement in cellular processes.
  • Investigation of Pak interactions in tumorigenesis.

Main Results:

  • Pak overexpression in cancer cells enhances migration, anchorage-independent growth, and mitotic abnormalities.
  • Pak dysregulation is observed in various human cancers.
  • Novel Pak-interacting proteins offer new insights into Pak functions.

Conclusions:

  • Paks play significant roles in fundamental cellular processes.
  • Aberrant Pak activity is a key factor in tumorigenesis.
  • Further research into Pak interactions is crucial for understanding and targeting cancer.

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...
Inhibition of CDK Activity02:34

Inhibition of CDK Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...